Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of Asthma Exacerbation in Children by Modified Pulmonary Index Score

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03190759
Recruitment Status : Not yet recruiting
First Posted : June 19, 2017
Last Update Posted : June 19, 2017
Sponsor:
Information provided by (Responsible Party):
Hend Heshmat, Assiut University

Brief Summary:

Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiatory airflow limitation. This definition was reached by consensus, based on consideration of the characteristics that are typical of asthma and that distinguish it from other respiratory conditions .

Asthma is a problem worldwide, with an estimated 300 million affected individuals .It appears that the global prevalence of asthma ranges from 1% to 18% of the population in different countries .


Condition or disease
Bronchial Asthma

  Show Detailed Description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Assessment of the Severity of Acute Asthma Exacerbation in Children Attending the Emergency Departments to Predict Outcomes by Modified Pulmonary Index Score
Estimated Study Start Date : November 11, 2017
Estimated Primary Completion Date : December 22, 2017
Estimated Study Completion Date : October 20, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma




Primary Outcome Measures :
  1. ICU admission according to oxygen saturation <81%, respiratory rate <6years old = >60 ≥6years old = >50 and heart rate <3 years old = >160 ≥3 years old= >140 [ Time Frame: within 15 minute ]
    Adequate evaluation of the severity of asthma exacerbation is important for the initial management of patients,using clinical parameters to decide ICU admission :oxygen saturation ,heart rate,respiratory rate and Degree of agitation and conscious level.


Secondary Outcome Measures :
  1. hospital stay [ Time Frame: within one week ]
    we will assess all patients with asthma by using parameters which included in modified pulmonary index score"namely heart rate, respiratory rate, accessory muscle use, inspiratory-to expiratory flow ratio, degree of wheezing, and oxygen saturation in room air." using score in predicting hospital stay



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
all patient admitted to emergency department of assiut university within three months of winter of anticipated number 60
Criteria

Inclusion Criteria:

  • children with acute asthma exacerbation
  • children with acute asthma aged 1-17 years old
  • background history of asthma
  • this study will deal with the protocols applied in Assiut university children hospital

Exclusion Criteria:.

  • children below age of 1 year and more than 17 years old
  • Known Tuberculosis exposure
  • concurrent stridor
  • use of oral corticosteroids in the previous four weeks
  • Significant co-morbid disease : lung ,cardiac ,immune , liver , endocrine ,neurological or psychiatric
  • children with other causes of respiratory distress
  • Children with mild or controlled asthma.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03190759


Contacts
Layout table for location contacts
Contact: . Moustafa El -Said, Professor 01110277000 moustafa13@yahoo.com
Contact: Eman askar, Assistant 01099696173 emanAsker@hotmail.com

Sponsors and Collaborators
Assiut University

Publications of Results:
Layout table for additonal information
Responsible Party: Hend Heshmat, prinicpal investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03190759     History of Changes
Other Study ID Numbers: asmpis
First Posted: June 19, 2017    Key Record Dates
Last Update Posted: June 19, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases